Differences ID'd in Tau Burden in Down Syndrome, Alzheimer Disease
THURSDAY, April 25, 2024 -- The spatial distribution, timing, and magnitude of tau burden differs for people with Down syndrome and those with autosomal-dominant Alzheimer disease, according to a study published in the May issue of The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2024 Category: Pharmaceuticals Source Type: news
Biogen ’s Leqembi beats analyst sales estimates in first quarter
The rollout of Biogen's Alzheimer's disease drug has picked up steam — but the company says don’t expect to see big revenue growth in 2024. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 24, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Investor Update - April 24, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Media News - April 24, 2024 Category: Pharmaceuticals Source Type: news
Novel Agent Curbs Alzheimer's-Related Agitation Novel Agent Curbs Alzheimer's-Related Agitation
AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer ' s disease in the phase 3 ACCORD trial.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 23, 2024 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
Alzheimer's Drug Skepticism; Safeguarding Brain Data; Benefits of Stimulating Jobs
(MedPage Today) -- Physicians treating Alzheimer's patients discussed why they're hesitant to prescribe lecanemab (Leqembi). (Reuters)
Researchers reviewed the role of neurofilament proteins in multiple sclerosis (MS), Alzheimer's disease, frontotemporal... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 23, 2024 Category: Neurology Source Type: news
Cognitive function following early life war-time stress exposure in a cohort of Vietnamese older adults - Korinek K, Zimmer Z, Teerawichitchainan B, Young Y, Cao Manh L, Toan TK.
Although Alzheimer's Disease is a leading cause of death in Vietnam and other post-conflict, low- and middle-income countries, aside from studies of veterans in western populations, research on war-related violence and deprivation as risk factors for cogni... (Source: SafetyLit)
Source: SafetyLit - April 22, 2024 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
One Neurological Factor Keeps Black, Hispanic Patients From Alzheimer's Clinical Trials
FRIDAY, April 19, 2024 -- Black and Hispanic patients with Alzheimer ’s disease are greatly underrepresented in clinical trials, even though they’re more likely to get dementia than whites.However, racial discrimination may not be driving this... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2024 Category: General Medicine Source Type: news
Alzheimer's Agitation Relapse Delayed With Dextromethorphan-Bupropion
(MedPage Today) -- DENVER -- Dextromethorphan-bupropion (known as AXS-05) delayed time to relapse in patients with Alzheimer's-related agitation, according to a phase III trial presented here.
Compared with placebo, AXS-05 increased the time... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 17, 2024 Category: Psychiatry Source Type: news
Agitation Relapse Delayed With Dextromethorphan-Bupropion
(MedPage Today) -- DENVER -- Dextromethorphan-bupropion (known as AXS-05) delayed time to relapse in patients with Alzheimer's-related agitation, according to a phase III trial presented here.
Compared with placebo, AXS-05 increased the time... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 17, 2024 Category: Psychiatry Source Type: news
Swoop system tested in Alzheimer ’s patients
Portable MRI developer Hyperfine has enrolled the first patients in a trial to test its Swoop system in Alzheimer’s disease patients undergoing amyloid-targeting therapy.
The CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study is designed to assess the clinical utility and workflow benefits of Swoop system. Imaging will be performed at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIAs) in Alzheimer’s patients.
The study is led by Tammie Benzinger, MD, PhD, a professor of radiology and chief of MRI service at the Mallinckrodt Institute of Radi...
Source: AuntMinnie.com Headlines - April 17, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Could Some HIV Meds Also Fight Alzheimer's?
WEDNESDAY, April 17, 2024 -- In a new study, people living with HIV who got standard meds to keep the virus at bay also had much lower rates of Alzheimer ' s disease -- suggesting the drugs might also lower risks for the brain illness.It ' s... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2024 Category: General Medicine Source Type: news
Common HIV treatments may aid Alzheimer & #039;s disease patients
Alzheimer's disease (AD) currently afflicts nearly seven million people in the U.S. With this number expected to grow to nearly 13 million by 2050, the lack of meaningful therapies represents a major unmet medical need. Scientists at Sanford Burnham Prebys have now identified promising real-world links between common HIV drugs and a reduced incidence of AD. The study, led by Jerold Chun, M.D., Ph.D., was published in Pharmaceuticals.
Chun's new research builds on his lab's landmark publication in Nature in 2018 that described how somatic gene recombination in neurons can produce thousands of new gene variants within Alz...
Source: World Pharma News - April 17, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Roche ’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III...
Source: Roche Media News - April 17, 2024 Category: Pharmaceuticals Source Type: news
Ozempic Hurts the Fight Against Eating Disorders
It’s impossible to escape the soaring popularity of Ozempic and similar drugs these days—daily headlines, celebrity “success” stories, and apparent ease in procuring prescriptions (even Costco sells them now) abound. But the cumulative effect of all of this has many experts in the eating disorder field worried about how this might affect their patients. This makes sense—even for those without eating disorders, these drugs can feel both triggering and enticing. After all, research tells us about 90% of women are dissatisfied with their bodies. This sounds like a quick fix.
[time-brightcove not-...
Source: TIME: Health - April 16, 2024 Category: Consumer Health News Authors: Cole Kazdin Tags: Uncategorized freelance Source Type: news
